• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates.

作者信息

Kromer W, Krüger U, Huber R, Hartmann M, Steinijans V W

机构信息

Department of Pharmacology, Byk Gulden, Konstanz, Germany.

出版信息

Pharmacology. 1998 Feb;56(2):57-70. doi: 10.1159/000028183.

DOI:10.1159/000028183
PMID:9494064
Abstract

Gastric proton pump inhibitors (PPIs) are substituted benzimidazole prodrugs that require an acid-induced activation. Its rate depends on the reactivity of the molecule relative to the environmental pH and determines the drug's tissue selectivity. Factors affecting the exposure of moderately acidic tissues to the activated PPI are the area under the serum concentration-time curve (AUC), serum protein binding, the partition coefficient logP and the serum elimination half-life relative to the chemical activation half-life at a critical tissue pH of about 5. These parameters have therefore been determined in a comparative fashion in the present study. The data shows that pantoprazole is less likely to undergo unwanted activation at moderately acidic targets as opposed to the parietal cell, compared to omeprazole. Actually, although 40 mg pantoprazole (steady state) gave a slightly higher serum AUC of the total parent compound than 40 mg omeprazole (10.5 vs. 7.1 micromol x h x l[-1]), a higher serum protein binding of pantoprazole versus omeprazole (98 vs. 96%) reversed the AUC values for the free drug in favor of a lower value for pantoprazole (0.19 vs. 0.28 micromol x h x l[-1]). It is the free parent compound that equilibrates across cell membranes to be activated in acidic tissue compartments. At pH 5.1, the activation half-life of pantoprazole was 4.7 versus 1.4 h for omeprazole, the latter being in the order of the common serum elimination half-life determined in an intraindividual comparison (1.24 vs. 1.25 h). Thus, pantoprazole is eliminated faster from blood than it is activated at a pH of about 5, while omeprazole is as quickly activated at this pH as it is eliminated from blood. Biological in vitro experiments confirmed that pantoprazole displays a lower liability to interfere with unwanted biological targets. This has been demonstrated in vitro for inhibition of both renal Na+/K+-ATPase, lysosomal acidification and the production of reactive oxygen species by neutrophils.

摘要

相似文献

1
Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates.
Pharmacology. 1998 Feb;56(2):57-70. doi: 10.1159/000028183.
2
Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.基于毫克的胃质子泵抑制剂的相对疗效:预期和非预期的SH反应。手性的影响。
Scand J Gastroenterol Suppl. 2001(234):3-9. doi: 10.1080/003655201753265389.
3
Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.与奥美拉唑相比,单次及重复口服质子泵抑制剂泮托拉唑后的24小时胃内pH值曲线及药代动力学。
Aliment Pharmacol Ther. 1996 Jun;10(3):359-66. doi: 10.1111/j.0953-0673.1996.00359.x.
4
Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.酸泵抑制剂的药代动力学、代谢及相互作用。重点关注奥美拉唑、兰索拉唑和泮托拉唑。
Clin Pharmacokinet. 1996 Jul;31(1):9-28. doi: 10.2165/00003088-199631010-00002.
5
Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds.取代苯并咪唑类化合物性质的异同:泮托拉唑与相关化合物的比较
Digestion. 1995;56(6):443-54. doi: 10.1159/000201275.
6
Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole.质子泵抑制剂奥美拉唑和泮托拉唑抑制期间胃酸分泌与质子泵活性之间的相关性。
Biochem Pharmacol. 1999 Oct 15;58(8):1349-59. doi: 10.1016/s0006-2952(99)00211-7.
7
Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.质子泵抑制剂奥美拉唑、兰索拉唑和泮托拉唑在人体中的比较药代动力学/药效学分析。
Eur J Drug Metab Pharmacokinet. 1998 Jan-Mar;23(1):19-26. doi: 10.1007/BF03189822.
8
Pantoprazole: a novel H+/K(+)-ATPase inhibitor with an improved pH stability.泮托拉唑:一种具有改善的pH稳定性的新型H⁺/K⁺-ATP酶抑制剂。
Eur J Pharmacol. 1992 Aug 6;218(2-3):265-71. doi: 10.1016/0014-2999(92)90178-7.
9
Pharmacokinetics--a relevant factor for the choice of a drug?药代动力学——药物选择的一个相关因素?
Aliment Pharmacol Ther. 1994;8 Suppl 1:25-32. doi: 10.1111/j.1365-2036.1994.tb00225.x.
10
Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers.奥美拉唑/泮托拉唑与克拉霉素在健康志愿者体内的药代动力学相互作用。
Pharmacol Res. 2004 May;49(5):493-9. doi: 10.1016/j.phrs.2003.10.010.

引用本文的文献

1
Repurposing of rabeprazole as an anti- drug that targets cellular triosephosphate isomerase.将雷贝拉唑重新用于靶向细胞三磷酸甘油醛异构酶的抗药物。
J Enzyme Inhib Med Chem. 2023 Dec;38(1):2231169. doi: 10.1080/14756366.2023.2231169.
2
Does the Use of Proton Pump Inhibitors Increase the Risk of Pancreatic Cancer? A Systematic Review and Meta-Analysis of Epidemiologic Studies.使用质子泵抑制剂会增加患胰腺癌的风险吗?一项流行病学研究的系统评价和荟萃分析。
Cancers (Basel). 2020 Aug 8;12(8):2220. doi: 10.3390/cancers12082220.
3
Proton Pump Inhibitors Modulate Transport Of Doxorubicin And Its Liposomal Form Into 2D And 3D Breast Cancer Cell Cultures.
质子泵抑制剂调节阿霉素及其脂质体形式向二维和三维乳腺癌细胞培养物中的转运。
Cancer Manag Res. 2019 Nov 21;11:9761-9769. doi: 10.2147/CMAR.S224097. eCollection 2019.
4
Overcoming transporter-mediated multidrug resistance in cancer: failures and achievements of the last decades.克服癌症中的转运蛋白介导的多药耐药性:过去几十年的失败与成就。
Drug Deliv Transl Res. 2019 Feb;9(1):379-393. doi: 10.1007/s13346-018-0584-7.
5
Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines.雷贝拉唑对人胃癌细胞系具有抗增殖作用。
Oncol Lett. 2014 Oct;8(4):1739-1744. doi: 10.3892/ol.2014.2354. Epub 2014 Jul 16.
6
Antiplatelet drug interactions with proton pump inhibitors.抗血小板药物与质子泵抑制剂的相互作用。
Expert Opin Drug Metab Toxicol. 2014 Feb;10(2):175-89. doi: 10.1517/17425255.2014.856883. Epub 2013 Nov 9.
7
Comparative anti-ulcerogenic study of pantoprazole formulation with and without sodium bicarbonate buffer on pyloric ligated rat.泮托拉唑制剂含与不含碳酸氢钠缓冲剂对幽门结扎大鼠的抗溃疡作用比较研究
J Pharmacol Pharmacother. 2011 Jul;2(3):179-84. doi: 10.4103/0976-500X.83283.
8
Pantoprazole: a proton pump inhibitor.泮托拉唑:一种质子泵抑制剂。
Clin Drug Investig. 2009;29 Suppl 2:3-12. doi: 10.2165/1153121-S0-000000000-00000.
9
Recent in vitro findings of negative inotropy of pantoprazole did not translate into clinically relevant effects on left ventricular function in healthy volunteers.近期关于泮托拉唑负性肌力作用的体外研究结果并未转化为对健康志愿者左心室功能的临床相关影响。
Clin Res Cardiol. 2009 Jun;98(6):391-9. doi: 10.1007/s00392-009-0012-6. Epub 2009 Mar 20.
10
A review of rabeprazole in the treatment of acid-related diseases.雷贝拉唑治疗酸相关性疾病的研究进展。
Ther Clin Risk Manag. 2007 Jun;3(3):363-79.